Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

Estimación de la elegibilidad para los inhibidores de la proproteína convertida subtilisina/kexina tipo 9 y los costos asociados basados en el ensayo FOURIER (Investigación de resultados cardiovasculares adicionales con inhibición de PCSK9 en sujetos de alto riesgo): información del Departamento de Asuntos de Veteranos

Salim S Virani ¹, Julia M Akeroyd ², Vijay Nambi ²

¹From Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, TX (S.S.V., J.M.A., L.A.P.); Sections of Health Services Research (S.S.V., J.M.A., L.A.P.) and Cardiovascular Research (S.S.V., V.N., C.M.B.), Department of Medicine, Baylor College of Medicine, Houston, TX; Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.S.V., V.N.); Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX (S.S.V., V.N., C.M.B.); Veterans Affairs Health System, Palo Alto, CA (P.A.H.); Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, CA (P.A.H.); Medical University of South Carolina, Charleston (P.B.M.); Center for Healthcare Advancement & Outcomes at Baptist Health South Florida, Miami (K.N.); Ciccarone Center for Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD (E.D.M.); and Division of Cardiovascular Disease, University of Alabama, Birmingham (V.A.B.). virani@bcm.edu.
²From Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, TX (S.S.V., J.M.A., L.A.P.); Sections of Health Services Research (S.S.V., J.M.A., L.A.P.) and Cardiovascular Research (S.S.V., V.N., C.M.B.), Department of Medicine, Baylor College of Medicine, Houston, TX; Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.S.V., V.N.); Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX (S.S.V., V.N., C.M.B.); Veterans Affairs Health System, Palo Alto, CA (P.A.H.); Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, CA (P.A.H.); Medical University of South Carolina, Charleston (P.B.M.); Center for Healthcare Advancement & Outcomes at Baptist Health South Florida, Miami (K.N.); Ciccarone Center for Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD (E.D.M.); and Division of Cardiovascular Disease, University of Alabama, Birmingham (V.A.B.).

⁰From Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, TX (S.S.V., J.M.A., L.A.P.); Sections of Health Services Research (S.S.V., J.M.A., L.A.P.) and Cardiovascular Research (S.S.V., V.N., C.M.B.), Department of Medicine, Baylor College of Medicine, Houston, TX; Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX (S.S.V., V.N.); Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX (S.S.V., V.N., C.M.B.); Veterans Affairs Health System, Palo Alto, CA (P.A.H.); Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, CA (P.A.H.); Medical University of South Carolina, Charleston (P.B.M.); Center for Healthcare Advancement & Outcomes at Baptist Health South Florida, Miami (K.N.); Ciccarone Center for Prevention of Heart Disease, Johns Hopkins University, Baltimore, MD (E.D.M.); and Division of Cardiovascular Disease, University of Alabama, Birmingham (V.A.B.). virani@bcm.edu.

Circulation +

|

4 de mayo de 2017

Resumen

No abstract available on PubMed

Palabras clave:

Enfermedad cardiovascular el colesterol Los lípidos